Form 4: Ligand Pharmaceuticals CEO Acquires Shares Through Employee Stock Purchase Plan

Todd C. Davis, CEO and Director of Ligand Pharmaceuticals Inc., acquired 233 shares of common stock through an employee stock purchase plan.

Summary

• Todd C. Davis, the Chief Executive Officer and a Director of Ligand Pharmaceuticals Inc. (LGND), acquired 233 shares of common stock.
• The transaction occurred on June 30, 2025, at a price of $91.0775 per share.
• These shares were acquired under the Ligand Employee Stock Purchase Plan (ESPP) and are exempt under SEC Rules 16b-3(d) and 16b-3(c).
• Following this acquisition, Todd C. Davis beneficially owns 161,467 shares of common stock directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates continued insider investment in the company, albeit through a routine employee benefit plan rather than a discretionary open-market purchase. The small size of the transaction limits its overall positive impact.

Positives

• The acquisition of shares by the CEO, Todd C. Davis, through an Employee Stock Purchase Plan indicates continued personal investment in the company's equity.
• The transaction is part of a pre-arranged plan (ESPP), suggesting a systematic approach to increasing insider ownership.

Future Outlook

The document does not provide any forward-looking statements or guidance beyond the details of the reported transaction.

Management Comments

• Shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Industry Context

This Form 4 filing details a routine insider transaction, specifically an acquisition through an Employee Stock Purchase Plan, which is a common benefit offered by publicly traded companies across various industries to encourage employee ownership and alignment with shareholder interests. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a standard component of compensation packages in many U.S. public companies, including those in the biotechnology and pharmaceutical sectors like Ligand Pharmaceuticals. The acquisition of shares through such a plan by a CEO is consistent with common corporate governance practices aimed at aligning management incentives with shareholder value.
• The reported transaction size of 233 shares is relatively small for a CEO of a company like Ligand Pharmaceuticals, which has a market capitalization in the billions. Larger open-market purchases by executives often signal stronger conviction, whereas ESPP acquisitions are more indicative of participation in a standard benefit program.

Related Party Transactions

• The acquisition of common stock by Todd C. Davis, the CEO and Director, through the Ligand Employee Stock Purchase Plan, constitutes a related party transaction as it involves a company executive and the issuer.

Stakeholder Impact

• Shareholders: The transaction shows continued, albeit small, alignment of the CEO's interests with shareholders through increased equity ownership.
• Employees: The mention of the Employee Stock Purchase Plan highlights a benefit program available to employees, which can foster a sense of ownership and align employee interests with company performance.

Key Dates

Recommendation

Keywords

Ligand Pharmaceuticals, LGND, Todd C. Davis, CEO, Director, Insider Trading, SEC Form 4, Stock Purchase Plan, ESPP, Common Stock, Beneficial Ownership